Thera-SAbDab

EDRECOLOMAB

>   Structural Summary
TherapeuticEdrecolomab
TargetEPCAM
Heavy ChainQVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGSGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARDGPWFAYWGQGTLVTVSA
Light ChainNIVMTQSPKSMSMSVGERVTLTCKASENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVPDRFTGSGSATDFTLTISSVQAEDLADYHCGQGYSYPYTFGGGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2a
Highest Clinical Trial (June '19)Approved (w)
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed1995
INN Year Recommended1996
Companies InvolvedAjinomoto, Centocor Inc
Conditions ApprovedColorectal cancer
Conditions Activena
Conditions DiscontinuedAdenocarcinoma, Pancreatic cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]